Lenalidomide Devatis

Lenalidomide, the active ingredient in Lenalidomide Devatis, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with 5q deletion, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Devatis as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies and clinics worldwide from its EU‑sourced manufacturing network while adhering to stringent quality standards and regulatory requirements.

Lenalidomide is used in hematologic malignancies, where it modulates immune and tumor cell pathways.

Multiple myeloma: improves progression‑free survival and overall response rates. Myelodysplastic syndromes with 5q deletion: induces transfusion independence and cytogenetic remission. Mantle cell lymphoma: contributes to disease control in combination regimens.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels leading to bleeding tendencies. - Anemia: decreased red blood cell production causing fatigue. - Fatigue: general tiredness and reduced stamina. - Diarrhea: loose stools that may affect hydration. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatic toxicity: elevated liver enzymes or liver injury. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Interstitial lung disease: inflammation of lung tissue causing respiratory symptoms.

Before initiating therapy, clinicians should assess baseline laboratory values and patient risk factors.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess thrombotic risk: evaluate history of clotting disorders and consider prophylaxis. Avoid in pregnancy: teratogenic; ensure effective contraception. Use caution in renal impairment: adjust dose based on renal function. Store at below 25°C: keep in the original pack, protect from moisture.

Lenalidomide may interact with other agents, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure. - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Immunosuppressants (e.g., cyclosporine): increased myelosuppression.

Moderate Interactions (Monitor Closely): - Erythropoiesis‑stimulating agents: additive risk of thrombosis. - Other antineoplastic agents: overlapping myelosuppressive effects. - Live vaccines: reduced efficacy and potential infection risk.